Stockreport

Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers

UNUM THERAPEUTICS INC COMMON  (UMRX) 
Last unum therapeutics inc common earnings: 3/26 07:30 am Check Earnings Report
PDF -Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts [Read more]